As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2023 about E6(R3) Good Clinical Practice (GCP) Guideline can be found below.
As part of its advocacy program in the United States, ACRO submits regulatory comments to US regulators. This comment letter, submitted by ACRO to FDA in 2023 about E6(R3) Good Clinical Practice (GCP) Guideline can be found below.